Product
HB-adMSCs
Aliases
Hope Biosciences adipose derived mesenchymal stem cells
7 clinical trials
5 indications
Indication
Traumatic Brain InjuryIndication
COVID-19Indication
Multiple SclerosisIndication
Parkinson's diseaseIndication
Post COVID-19 SyndromeClinical trial
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic EncephalopathyStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II, Open Label, Single-Center, Clinical Trial to Assess Safety and Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus DiseaseStatus: Completed, Estimated PCD: 2020-11-25
Clinical trial
A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple SclerosisStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
"A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease"Status: Completed, Estimated PCD: 2023-02-06
Clinical trial
Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Patients With Post-COVID-19 SyndromeStatus:
Clinical trial
A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.Status: Completed, Estimated PCD: 2024-04-02